SGLT2 inhibitor
Sodium-glucose cotransporter 2 inhibitor
- Glucosuria and osmotic diuresis
- Cardiovascular and kidney protection beyond glucose lowering
- Genital mycotic infections and euglycemic ketoacidosis are mechanism-linked
- Blocks renal glucose reabsorption — glucosuria
- Cardiovascular and renal protection beyond glucose lowering
- Genital mycotic infection; euglycemic ketoacidosis
Drugs with this mechanism (7)
- Bexagliflozin — Lower-cost SGLT2 inhibitor for glycemic control in type 2 diabetes; outcome evidence is limited.
- Canagliflozin — SGLT2 inhibitor for diabetes; weight and BP benefit, genital infections.
- Dapagliflozin — SGLT2 inhibitor for diabetes, heart failure, and kidney disease.
- Empagliflozin — SGLT2 inhibitor with cardiovascular and renal outcome benefits.
- Ertugliflozin — SGLT2 inhibitor for type 2 diabetes; cardiovascular non-inferiority only, no CV/renal claim.
- Luseogliflozin — SGLT2 inhibitor used for type 2 diabetes in Japan; urinary glucose loss brings genital-infection and ketoacidosis risks.
- Sotagliflozin — Dual SGLT1/SGLT2 inhibitor for heart failure; intestinal blockade adds diarrhea.
All mechanisms · Open SGLT2 inhibitor in the interactive console ↗